Biocellvia performs completely automated digital image analysis for preclinical disease models.

With over a decade’s experience in industry and academia, Biocellvia is an uprising French startup whose proprietary automated image analysis has been rapidly adopted by the pharmaceutical industry. The milestone collaboration and co-publication with Boehringer Ingelheim further validated Biocellvia’s methodology in the pulmonary fibrosis murine model. Then, this intelligent image analysis has been developed for respiratory diseases such as pulmonary fibrosis, COPD, asthma. Biocellvia is now concentrating its R&D efforts on NASH, oncology and CNS.

The quality and robustness of the results generated by automatic quantitation will give you better confidence in your studies, help you bring clearer insights in front of stakeholders, and free up precious time and resources so you can bring focus back to the Science and accelerate towards the clinic.

Free Trial

Biocellvia has developed digital image analysis solutions for pre-clinical trials. It’s a new way to elaborate your candidate molecules thanks to machine-learning based programs.

We have developed digital image analysis solutions based on machine-learning in order to evaluate lead molecules during pre-clinical assays.

Conventional methods had major limits and laborious to use. 
I understood straight away the advantage of numerical imaging for the industry. Our proprietary technology is based on machine-learning and fully-automated imaging analysis to optimize compound validation assay. This technology applicable to different pathologies, for a clearer decision-making.

Yvon Jule

This is a breakthrough innovation for pharmaceutical industry.

Our digital technology enables to evaluate candidate molecules during pre-clinical assays. These numerical tests have full benefits :
  • Independent-observer removing any variability
  • Optimal accuracy to get quantitative data
  • Machine-learning based programs
  • Our technology reduces delays and costs

Our research & development process enables us to propose available tests for more and more pathologies

Our compound validation assays are machine-learning based programs. We have developed artificial intelligence in order to improve studies’ results in pre-clinical assays. Our tests are fully-automated and independent-observer.

Biocellvia’s approach to machine learning-based image analysis is unique in the industry as a commercial service provider. Our team of biologists and software developers work collaboratively to customize each program based on the specific, relevant biological context through carefully curated pilot studies. Our quantitative image analysis is completely automated and therefore reproducible and precise.  We perform the image analysis as a service on a needs basis.

The aim is to improve the accuracy and reliability of scientists’ analysis and as a result your decision-making while respecting specific processes.

Biocellvia news

octobre 24, 2018

Yvon Julé speaker at a World Conference dedicated to COPD

Yvon Julé, Biocellvia’s Chief Scientific Officer was at a World Conference dedicated to COPD in Roma (Italy) from October 22nd to 24th. He was invited as […]
août 31, 2018

IPF summit : very good opportunities for Biocellvia

Biocellvia took part to the IPF summit in San Francisco from August 20th to 22nd. This event gathered more than 100 worldwide experts on Idiopathic Pulmonary […]

Used in more than



Since 2013


samples analyzed

More than


years experience

1 technology